SEC Form SC 13G filed by Rain Oncology Inc.

$RAIN
Industrial Machinery/Components
Technology
Get the next $RAIN alert in real time by email
SC 13G 1 formsc13g112423rain.htm




SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

SCHEDULE 13G*
(Rule 13d-102)

INFORMATION TO BE INCLUDED
IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND
(d) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2
(AMENDMENT NO.     )*

 
Rain Oncology Inc.
 
 
Common Stock, par value $0.001 per share
 
 
75082Q105
 
 
November 13, 2023
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 

 

 
1
NAMES OF REPORTING PERSONS
 
 
 BML Investment Partners, L.P.
 
 
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
   
(a)
   
(b)☒
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
 Delaware
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5
SOLE VOTING POWER
 
 
 0
 
 
 
 
6
SHARED VOTING POWER
 
 
 1,315,025
 
 
 
 
7
SOLE DISPOSITIVE POWER
 
 
 0
 
 
 
 
8
SHARED DISPOSITIVE POWER
 
 
 1,315,025
 
 
 
 
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
 1,315,025
 
 
 
 
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
 
 
 
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
 
 4.8%
 
 
 
 
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
 
 PN
 
 
 
 
 



1
NAMES OF REPORTING PERSONS
 
 
 Braden M Leonard
 
 
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
   
(a)
   
(b)☒
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
 United States
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5
SOLE VOTING POWER
 
 
 500,928
 
 
 
 
6
SHARED VOTING POWER
 
 
 1,315,025
 
 
 
 
7
SOLE DISPOSITIVE POWER
 
 
 500,928
 
 
 
 
8
SHARED DISPOSITIVE POWER
 
 
 1,315,025
 
 
 
 
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
 1,815,953
 
 
 
 
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
 
 
 
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
 
 6.6
 
 
 
 
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
 
 IN
 
 
 
 

Item 1(a). Name of Issuer:

 Rain Oncology, Inc.
 
Item 1(b). Address of Issuer's Principal Executive Offices:
 
      
    8000 Jarvis AvenueSuite 204
NewarkCA

Item 2(a). Name of Person Filing:

 BML Investment Partners, L.P.
 

Item 2(b). Address of Principal Business Office or, if none, Residence:
 
 
65 E Cedar, Suite 2
Zionsville, IN 46077

Item 2(c). Citizenship:

 Delaware

Item 2(d). Title of Class of Securities:

 


Common Stock, par value $0.01 per share

 
Item 2(e). CUSIP Number:

 75082Q105


Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


(a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


(b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


(c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


(d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


(e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


(f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


(g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


(h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


(i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


(j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


(k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
 
Item 4. Ownership.


(a) Amount beneficially owned: 1,815,953


(b) Percent of class: 6.6%


(c) Number of shares as to which the person has:


(i) Sole power to vote or to direct the vote: 500,928


(ii) Shared power to vote or to direct the vote: 1,315,025

  (iii) Sole power to dispose or to direct the disposition of: 500,928

  (iv) Shared power to dispose or to direct the disposition of: 1,315,025
 


Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

n/a
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 n/a

Item 8. Identification and Classification of Members of the Group.

 n/a

Item 9. Notice of Dissolution of Group.

 n/a
 
Item 10.
Certification.
 
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
 


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:November 24, 2023
 
 
BML Capital Management, LLC
 
 
By:
 /s/ Braden M Leonard
   
Name:  Braden M Leonard
   
Title:   Managing Member
 
 
 

Get the next $RAIN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RAIN

DatePrice TargetRatingAnalyst
5/30/2023Buy → Neutral
ROTH MKM
3/21/2023$11.00Outperform
SVB Securities
1/31/2023$21.00Buy
ROTH Capital
1/23/2023$18.00Buy
Mizuho
9/12/2022$10.00Buy
H.C. Wainwright
4/1/2022$15.00Outperform
Oppenheimer
9/14/2021$22.00Neutral
Goldman
7/20/2021$25.00Overweight
Piper Sandler
More analyst ratings

$RAIN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

    Technology Industry Veteran With Over 30 Years Of Enterprise Leadership Experience To Accelerate RET's Growth And Commercialization Strategy Rain Enhancement Technologies Holdco, Inc. ("RET Holdco" or the "Company") (NASDAQ:RAIN, RAINW)), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer ("CEO") of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. ("RET"). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings over three decades of experience scaling technology companies and driving revenue growth.

    $ONDS
    $RAIN
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Industrial Machinery/Components
  • Pathos AI Completes Acquisition of Rain Oncology

    Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. ("Pathos") today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. ("Merger Sub"), successfully completed its tender offer to acquire all outstanding shares of the common stock of Rain Oncology Inc. (NASDAQ:RAIN) ("Rain") for $1.16 per share in cash plus one contingent value right per share (each, a "CVR"), which CVR shall represent the right to receive potential payments pursuant to the terms and subject to the conditions of the Contingent Value Rights Agreement, dated as of January 26, 2024, by and among Pathos, Merger Sub, Equiniti Trust Company, LLC, and Forti

    $RAIN
    Industrial Machinery/Components
    Technology
  • Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights

    NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN) ("Rain"), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. ("Pathos") will acquire Rain for $1.16 in cash per share plus a non-tradeable contingent value right (a "CVR") for potential cash payments of up to approximately $0.17 per share. The Rain Board of Directors voted unanimously to approve the proposed Offer, Merger and related transactions contemplated by the Merger Agreement (collectively, the "Transaction"). The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13, 2023. The Rain Board reached this determinati

    $RAIN
    Industrial Machinery/Components
    Technology

$RAIN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RAIN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$RAIN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RAIN
SEC Filings

See more

$RAIN
Leadership Updates

Live Leadership Updates

See more
  • Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer

    Technology Industry Veteran With Over 30 Years Of Enterprise Leadership Experience To Accelerate RET's Growth And Commercialization Strategy Rain Enhancement Technologies Holdco, Inc. ("RET Holdco" or the "Company") (NASDAQ:RAIN, RAINW)), an emerging company developing rainfall generation technology, today announced that Randy Seidl has been appointed as Chief Executive Officer ("CEO") of RET Holdco and of its wholly-owned subsidiary, Rain Enhancement Technologies, Inc. ("RET"). Seidl has served as Co-Chief Executive Officer and a member of the Board of Directors since January 2, 2025. Seidl brings over three decades of experience scaling technology companies and driving revenue growth.

    $ONDS
    $RAIN
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Industrial Machinery/Components

$RAIN
Financials

Live finance-specific insights

See more
  • Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

    – Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3 million expected to provide runway into year-end 2026 – – Management to host conference call and webcast today at 2:00 pm PT/5:00 pm ET – NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), today reports financial results for the second quarter ended June 30, 2023, and provides a corporate update. "Rain has been aggressively pursuing a multitude of opportunities as we seek to leve

    $RAIN
    Industrial Machinery/Components
    Technology
  • Rain Oncology to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on August 10, 2023

    NEWARK, Calif., July 26, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), ("Rain") today announced it will report financial results for the second quarter ended June 30, 2023 and provide a corporate update on Thursday, August 10, 2023. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company's business and financial results. Conference Call and Webcast Details: Date: August 10, 2023Time: 2:00 pm PT (5:00 pm ET)Dial In Numbers: 1 (888) 886-7786 (U.S. Toll Free) / 1 (416) 764-8658 (International)Conference ID: 29873479Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1624922&tp_key=7933f8175f A replay of the ca

    $RAIN
    Industrial Machinery/Components
    Technology
  • Rain Oncology Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for the Treatment of Dedifferentiated Liposarcoma

    – The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a conference call at 8:30 a.m. ET – NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NASDAQ:RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced its topline pivotal Phase 3 MANTRA data. The trial, evaluating the efficacy, safety, and tolerability of milademetan in p

    $RAIN
    Industrial Machinery/Components
    Technology

$RAIN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more